A clinical-stage biotechnology company developing small-molecule therapies for neurological disorders, with a focus on epilepsy and other conditions linked to ion channel dysfunction. Its lead drug candidates target potassium channels and other mechanisms involved in seizure activity and neurologica...
1 member of Congress has disclosed 1 trade in Xenon Pharmaceuticals Inc. (XENE), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-03-02 | MICHAEL T. MCCAUL | buy | $1K – $15K |